Modulation of Muscle Protein Metabolism by Essential Amino Acids
NCT ID: NCT01890369
Last Updated: 2014-01-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
32 participants
INTERVENTIONAL
2013-04-30
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Amino Acid on Muscle Damage
NCT03319147
Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance With Age; the Role of Amino Acids in Modulating Muscle Metabolism
NCT01735539
Effect of Non-essential Amino Acids on Protein Requirements for Endurance Athletes
NCT02874638
Dietary Intake and Circulating Levels of Branched Chain Amino Acids
NCT02110602
Determination of the UL of Leucine in Healthy Elderly Men
NCT02095080
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early leucine refeed
15g Mixed Essential Amino Acids. 90 min delay. 3g Leucine
15g Mixed Essential Amino Acids
Dissolved in 250ml water.
3g Leucine
Dissolved in 250ml water.
Early EAA refeed
15g Mixed Essential Amino Acids. 90 min delay. 15g Mixed Essential Amino Acid REFEED
15g Mixed Essential Amino Acids
Dissolved in 250ml water.
15g Mixed Essential Amino Acid REFEED
Dissolved in 250ml water.
Mid latency EAA refeed
15g Mixed Essential Amino Acids. 150 min delay. 15g Mixed Essential Amino Acid REFEED
15g Mixed Essential Amino Acids
Dissolved in 250ml water.
15g Mixed Essential Amino Acid REFEED
Dissolved in 250ml water.
Late latency EAA refeed
15g Mixed Essential Amino Acids. 210 min delay. 15g Mixed Essential Amino Acid REFEED
15g Mixed Essential Amino Acids
Dissolved in 250ml water.
15g Mixed Essential Amino Acid REFEED
Dissolved in 250ml water.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
15g Mixed Essential Amino Acids
Dissolved in 250ml water.
3g Leucine
Dissolved in 250ml water.
15g Mixed Essential Amino Acid REFEED
Dissolved in 250ml water.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 65-75yrs
* BMI 18-28
Exclusion Criteria
* Neurological Disease
* Significant cardiac, hepatic or renal disease
* Active malignancy
* Medication inc. Corticosteroids, NSAID use, Beta adrenoblockers.
65 Years
75 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ajinomoto Co., Inc.
INDUSTRY
University of Nottingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip J Atherton, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Nottingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
School of Graduate Entry Medicine
Derby, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B13122012 GEM BMS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.